pbpk modeling of tizanidine systemic exposure by cyp1a2 modulation: impact of ddis & smoking
Published 3 years ago • 835 plays • Length 53:33Download video MP4
Download video MP3
Similar videos
-
59:17
strategic application of pbpk models for predicting ddis & the effects of smoking & organ impairment
-
55:43
pbpk modelling to predict drug-biologic interactions with cytokine modulators
-
55:55
itraconazole – comparison of pbpk models for evaluation of clinical pk exposure and ddis
-
1:06:27
the importance of pbpk model validation and reproducibility in obstetric pharmacology
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
1:02:16
leveraging dermal pbpk modeling and simulation approaches
-
50:49
pbpk modeling and simulation for regulatory decision making: impact on us prescribing information
-
1:01:14
pbpk modeling & simulation to support asciminib nda submission and inform drug product label
-
46:19
tizanidine and cyp1a2 inhibitors
-
53:13
food constituent–drug interactions: influence of quantitative modelling on drug labelling
-
1:02
idexx - petchek ip wellness testing
-
29:43
simulating cytokine-related therapeutic protein – ddi using simcyp’s tp-modulator module
-
9:03
accufit9000 | face fit testing | basystemen
-
50:00
obeticholic acid: from pk model to drug label
-
![bent-tip needle blood flow probe [mnp150nx]](https://i.ytimg.com/vi/dOgLlvMTqHA/mqdefault.jpg)
1:31
bent-tip needle blood flow probe [mnp150nx]
-
39:17
an introduction to pbpk, simcyp discovery, and the simcyp product suite
-
5:36
what is cyp2c19?
-
48:15
a pbpk platform model to guide intravenous and subcutaneous dosing for bispecific t cell engagers